Tolppanen AM, et al. - Researchers evaluated the use of systemic estrogen among community-dwellers with Alzheimer’s disease (AD) to assess the impact of cognitive status or diagnosed cognitive decline on estrogen use. Participants included an exposure-matched cohort of all Finnish community-dwelling women with a clinically verified diagnosis of AD (N=46,116; index cases) and an equally sized matched comparison cohort without AD. Findings revealed that Finnish women with AD showed no major differences in systemic estrogen use vs those without AD. In addition, the investigators noted initiation of estrogen use in some individuals following a diagnosis of AD and/or at an advanced age. According to results, use patterns were mainly consistent with the current recommendations.